Growth Metrics

Biolife Solutions (BLFS) Asset Writedowns and Impairment (2016 - 2022)

Biolife Solutions (BLFS) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $8.3 million as the latest value for Q3 2023.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $8.3 million in Q3 2023 year-over-year; TTM through Dec 2024 was $78.2 million, a N/A change, with the full-year FY2023 number at $9.7 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $8.3 million for Q3 2023 at Biolife Solutions, down from $69.9 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $69.9 million in Q2 2022 to a low of $8.3 million in Q3 2023.